Drug
LU Aa24530
LU Aa24530: highest development phase Phase 2, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AA24530 NCT00599911 | Phase 2 | Major Depressive Disorder |
Latest
No recent events.
Follow LU Aa24530 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.